Non-invasive actionable biomarkers for metastatic prostate cancer
In the current clinical setting, many disease management options are available for men diagnosed with prostate cancer. For metastatic prostate cancer, first-line therapies almost always involve agents designed to inhibit androgen receptor (AR) signaling. Castration-resistant prostate cancers (CRPCs)...
Saved in:
| Main Author: | Jun Luo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-10-01
|
| Series: | Asian Journal of Urology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388216300637 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
by: Gillian Vandekerkhove, Alexander Wyatt
Published: (2020-10-01) -
Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01) -
Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.
by: Deborah R Kaye, et al.
Published: (2016-01-01) -
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01) -
Immunotherapy in metastatic prostate cancer
by: Liam Dwyer, et al.
Published: (2025-06-01)